top of page


FDA Approves Lipfendra (enlicitide), the First Oral PCSK9 Inhibitor for LDL-C Reduction
Hypercholesterolemia occurs when blood levels of low-density lipoprotein cholesterol (LDL-C) are elevated (1). High LDL-C is a major modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD), which remains a leading cause of mortality worldwide and in the United States (1,2). Excess circulating LDL-C progressively deposits within arterial walls, accelerating plaque formation, narrowing vessels, and restricting blood flow. Plaque rupture can precipitate thrombo

Dr. Manisha Dadlani
Aug 285 min read
Â
Â
bottom of page